Menu Menu

Guidelines update, v40.2

17 June, 2021

Version 40.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of three new studies on disease-modifying treatments. In addition, the treatment ‘REGN-COV2’ has been renamed to ‘casirivimab plus imdevimab (REGEN-COV)’:

These studies are currently under review and will be incorporated in a future version of the guidelines.